End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.55 USD | +3.73% | 0.00% | +116.83% |
06-12 | Dianthus Therapeutics Secures US FDA Approval to Launch Phase 2 Study of DNTH103 in Multifocal Motor Neuropathy | MT |
06-12 | Dianthus Therapeutics Gets FDA Clearance for DNTH103 Phase 2 Trial | DJ |
Official Publications
No official publication found
- Stock Market
- Equities
- DNTH Stock
- News Dianthus Therapeutics, Inc.
- Official Publications